{"DataElement":{"publicId":"6400509","version":"1","preferredName":"Exposure Route of Administration","preferredDefinition":"The route of administration of the study treatment.","longName":"EXROUTE","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6384925","version":"1","preferredName":"Exposure Domain Exposure Route of Administration","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to exposure._Designation of the part of the body through which the exposure is introduced.","longName":"6384837v1.0:6384923v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6384837","version":"1","preferredName":"Exposure Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to exposure.","longName":"C49587","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exposure Domain","conceptCode":"C49587","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to exposure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72DDFC50-2B67-1CB3-E053-F662850A4DB7","latestVersionIndicator":"Yes","beginDate":"2018-08-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-07","modifiedBy":"ONEDATA","dateModified":"2018-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6384923","version":"1","preferredName":"Exposure Route of Administration","preferredDefinition":"Designation of the part of the body through which the exposure is introduced.","longName":"C83121","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exposure Route of Administration","conceptCode":"C83121","definition":"Designation of the part of the body through which the exposure is introduced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72DE86A7-70E4-1D22-E053-F662850AF2D5","latestVersionIndicator":"Yes","beginDate":"2018-08-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-07","modifiedBy":"ONEDATA","dateModified":"2018-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"72DE86A7-70F5-1D22-E053-F662850AF2D5","latestVersionIndicator":"Yes","beginDate":"2018-08-07","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-07","modifiedBy":"KUMMEROA","dateModified":"2021-06-15","changeDescription":"2021-6-15 ak Released per governance approval.; 8-7-18 Created as part of the CDISC mapping task; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6400460","version":"1","preferredName":"CDISC CDASH Exposure Route of Administration Terminology Type","preferredDefinition":"A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Route codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Exposure Route of Administration terminology._Something distinguishable as an identifiable class based on common qualities.","longName":"EXROUTE","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"TOPICAL","valueDescription":"Topical Route of Administration","ValueMeaning":{"publicId":"2577941","version":"1","preferredName":"Topical Route of Administration","longName":"2577941","preferredDefinition":"The application of a drug to a certain area of the skin or mucous membrane (including the intra-organ application), or other tissue locally, so that the agent will take effect on the surface and/or on the underlying tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical Route of Administration","conceptCode":"C38304","definition":"The application of a drug to a certain area of the skin or mucous membrane (including the intra-organ application), or other tissue locally, so that the agent will take effect on the surface and/or on the underlying tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD82-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-26","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-26","modifiedBy":"SBREXT","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3CB9-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"INTRALESIONAL","valueDescription":"Intralesional Route of Administration","ValueMeaning":{"publicId":"2578032","version":"1","preferredName":"Intralesional Route of Administration","longName":"2578032","preferredDefinition":"Administration within or introduced directly into a localized lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intralesional Route of Administration","conceptCode":"C38250","definition":"Administration of a drug within or introduced directly into a localized lesion. Method allows to achieve high concentration of the agent in the lesion and delay drug release in systemic circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDDD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3CC4-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"INTRAOCULAR","valueDescription":"Intraocular Route of Administration","ValueMeaning":{"publicId":"2578011","version":"1","preferredName":"Intraocular Route of Administration","longName":"2578011","preferredDefinition":"Administration within the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraocular Route of Administration","conceptCode":"C38255","definition":"Administration of a drug within the eye. Intraocular drugs are almost always used for their local effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3CCF-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"RECTAL","valueDescription":"Rectal Route of Administration","ValueMeaning":{"publicId":"2581011","version":"1","preferredName":"Rectal Route of Administration","longName":"2581011","preferredDefinition":"The introduction of a substance into the gastrointestinal tract by the way of the rectum, usually for systemic action. Depending on the molecular structure, drugs cross the rectal wall via either intercellular or tight junctions interconnecting the mucosal cells. Drug absorption is usually around 50% of normal oral dose. Due to the drainage pattern of the rectal veins, the hepatic first-pass effect tends to increase as the dosage form is placed deeper into the rectum. Solid suppositories represent greater than 98% of all rectal dosage forms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rectal Route of Administration","conceptCode":"C38295","definition":"The introduction of a substance into the gastrointestinal tract by the way of the rectum, usually for systemic action. Depending on the molecular structure, drugs cross the rectal wall via either intercellular or tight junctions interconnecting the mucosal cells. Drug absorption is usually around 50% of normal oral dose. Due to the drainage pattern of the rectal veins, the hepatic first-pass effect tends to increase as the dosage form is placed deeper into the rectum. Solid suppositories represent greater than 98% of all rectal dosage forms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0980-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-26","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-26","modifiedBy":"SBREXT","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3CE4-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"VAGINAL","valueDescription":"Vaginal Route of Administration","ValueMeaning":{"publicId":"5335398","version":"1","preferredName":"Vaginal Route of Administration","longName":"5335398","preferredDefinition":"Administration of a drug into the vagina. The medication usually has the form of a solution, tablet, cream, gel, or suppository. The drug is slowly absorbed through the vaginal wall with predominantly local, but some systemic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Route of Administration","conceptCode":"C38313","definition":"Administration of a drug into the vagina. The medication usually has the form of a solution, tablet, cream, gel, or suppository. The drug is slowly absorbed through the vaginal wall with predominantly local, but some systemic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9F0B-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3CF9-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"TRANSDERMAL","valueDescription":"Transdermal Route of Administration","ValueMeaning":{"publicId":"2581012","version":"1","preferredName":"Transdermal Route of Administration","longName":"2581012","preferredDefinition":"Administration of a substance through the dermal layer of the skin into the systemic circulation by diffusion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transdermal Route of Administration","conceptCode":"C38305","definition":"Administration of a substance through the dermal layer of the skin into the systemic circulation by diffusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0981-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-26","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-26","modifiedBy":"SBREXT","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3D0E-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"RESPIRATORY (INHALATION)","valueDescription":"Inhalation Route of Administration","ValueMeaning":{"publicId":"2577932","version":"1","preferredName":"Inhalation Route of Administration","longName":"2577932","preferredDefinition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inhalation Route of Administration","conceptCode":"C38216","definition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-26","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-26","modifiedBy":"SBREXT","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3D23-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"NASAL","valueDescription":"Nasal Route of Administration","ValueMeaning":{"publicId":"5335414","version":"1","preferredName":"Nasal Route of Administration","longName":"5335414","preferredDefinition":"Administration of a drug by the way of the nose. This often results in systemic action of the agent due to absorption through the nasal mucosa. The richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs, including proteins and peptides.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Route of Administration","conceptCode":"C38284","definition":"Administration of a drug by the way of the nose. This often results in systemic action of the agent due to absorption through the nasal mucosa. The richly supplied vascular nature of the nasal mucosa coupled with its high drug permeation makes the nasal route of administration attractive for many drugs, including proteins and peptides.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A03B-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3D38-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"INTRAMUSCULAR","valueDescription":"Intramuscular Route of Administration","ValueMeaning":{"publicId":"5335408","version":"1","preferredName":"Intramuscular Route of Administration","longName":"5335408","preferredDefinition":"Administration within a muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intramuscular Route of Administration","conceptCode":"C28161","definition":"Intramuscular injection is a route of drug administration via injection into muscle tissue. Aqueous or oleaginous solutions and emulsions or suspensions may be administered. Absorption rates, delay in availability of the drug to the systemic circulation, and duration of effect are perfusion-limited, depend on molecular size of the agent, volume, and osmolarity of the drug solution, fat content of the injection site, and patient physical activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-9FC9-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3D4D-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"SUBCUTANEOUS","valueDescription":"Subcutaneous Route of Administration","ValueMeaning":{"publicId":"5335421","version":"1","preferredName":"Subcutaneous Route of Administration","longName":"5335421","preferredDefinition":"Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Route of Administration","conceptCode":"C38299","definition":"Drug administration beneath the skin. It provides for relatively slow, sustained release of the drug. The rate of absorption into the blood is perfusion-limited, proportional to the amount of drug at the site and can be enhanced by chemical or physical stimulation of blood flow. Subcutaneous administration minimizes the risks associated with intravascular injection: for subcutaneous infusions, external and implantable pumps are used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"36E51D41-A0D2-74F7-E050-BB89AD4334C4","latestVersionIndicator":"Yes","beginDate":"2016-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3D62-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"INTRAPERITONEAL","valueDescription":"Intraperitoneal Route of Administration","ValueMeaning":{"publicId":"2578020","version":"1","preferredName":"Intraperitoneal Route of Administration","longName":"2578020","preferredDefinition":"Administration within the peritoneal cavity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraperitoneal Route of Administration","conceptCode":"C38258","definition":"Administration of a drug via injection or infusion of a substance into the peritoneum, where it is absorbed by the lining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDD1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3D6D-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"},{"value":"ORAL","valueDescription":"Oral Route of Administration","ValueMeaning":{"publicId":"2581009","version":"1","preferredName":"Oral Route of Administration","longName":"2581009","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-097E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-26","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-26","modifiedBy":"SBREXT","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"736A133D-3D77-3655-E053-F662850A6B4E","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6400459","version":"1","preferredName":"CDISC CDASH Exposure Route of Administration Terminology Type","preferredDefinition":"A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Route codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Exposure Route of Administration terminology.:Something distinguishable as an identifiable class based on common qualities.","longName":"C78425:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDISC CDASH Exposure Route of Administration Terminology","conceptCode":"C78425","definition":"A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Route codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Exposure Route of Administration terminology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"736A133D-3C88-3655-E053-F662850A6B4E","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"736A133D-3C99-3655-E053-F662850A6B4E","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"COOPERM","dateModified":"2021-05-27","changeDescription":"8-14-18 Created as part of the CDISC mapping task; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6338162","version":"1","longName":"CDISC (NCI Implementation)","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6338163","version":"1","longName":"CDASH","context":"NCI Standards"},{"publicId":"7329797","version":"1","longName":"Exposure (EX) Domain","context":"NCI Standards"},{"publicId":"7329810","version":"1","longName":"Recommended/Conditional Core","context":"NCI Standards"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685479","version":"1","longName":"Testing Set â€“ Semantically Different","context":"NCIP"}]}],"AlternateNames":[{"name":"EX.EXROUTE","type":"Map:CDASHv1.1","context":"NCIP"}],"ReferenceDocuments":[{"name":"What was the route of adminis","type":"Preferred Question Text","description":"What was the route of administration (of the study treatment)?","url":null,"context":"NCI Standards"},{"name":"CDASH PROMPT","type":"Alternate Question Text","description":"Route","url":null,"context":"NCI Standards"},{"name":"CDISC CDASH Exposure Route of Administration Terminology","type":"VALID_VALUE_SOURCE","description":"A terminology subset of the CDISC Study Data Tabulation Model (SDTM) Route codelist created for Clinical Data Acquisition Standards Harmonization (CDASH) Exposure Route of Administration terminology.","url":"https://ncit.nci.nih.gov/ncitbrowser/ajax?action=create_src_vs_tree&amp;vsd_uri=http%3A//evs.nci.nih.gov/valueset/CDISC/C78425","context":"NCI Standards"},{"name":"Case Report Form  Completion Instructions","type":"CDISC CRF Instruction","description":"Record the route of administration (e.g., IV, ORAL, TRANSDERMAL) or enter the appropriate code from the code list.","url":null,"context":"NCI Standards"},{"name":"EXROUTE","type":"CDASH to SDTM Mapping","description":"Maps directly to the SDTMIG variable.","url":null,"context":"NCI Standards"},{"name":"CDASH Implementation Notes","type":"CDASH Implementation Note","description":"This may be collected if it cannot be determined via other methods (e.g., from protocol) or if there are multiple options.","url":null,"context":"NCI Standards"}],"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"736A42D6-1E88-6089-E053-F662850A9ACF","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-14","modifiedBy":"KUMMEROA","dateModified":"2021-06-15","changeDescription":"2021-6-15 ak Released per governance approval. 8-14-18 Created as part of the CDISC mapping task; tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}